![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Argo has granted Novartis exclusive global licenses to develop and commercialize a Phase 1 stage program. Novartis can select up to two targets against which Argo will perform discovery and optimization, to deliver PCCs.
Lead Product(s): BW-02
Therapeutic Area: Cardiology/Vascular Diseases Product Name: BW-02
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $4,165.0 million Upfront Cash: $185.0 million
Deal Type: Licensing Agreement January 07, 2024